Skip to main content
Top
Published in: Clinical Rheumatology 5/2007

01-05-2007 | Original Article

High prevalence of metabolic syndrome in patients with ankylosing spondylitis

Authors: Domenico Malesci, Alferio Niglio, Gianna Angela Mennillo, Rosario Buono, Gabriele Valentini, Giovanni La Montagna

Published in: Clinical Rheumatology | Issue 5/2007

Login to get access

Abstract

The objective of this work is to investigate the occurrence of atherosclerosis and metabolic syndrome (MetS) in ankylosing spondylitis (AS) patients (pts). Twenty-four consecutive AS pts (men, 87.5%; median age, 50.5 years; median disease duration, 16.5 years), fulfilling the modified 1984 New York criteria for AS criteria, and 19 age- and sex-matched controls were investigated. Clinical atherosclerosis was evaluated by physical examination for cardiovascular (CV) diseases and history or drug use for CV events. Subclinical atherosclerosis was detected by mean intima media thickness (a-IMT) and maximum IMT (max-IMT) of carotid arteries using ultrasonography. Laboratory investigations including fasting plasma glucose, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides were assessed by standard methods, while homocysteine was assessed by chemiluminescence. MetS was assessed using the updated NCEP-ATP III criteria. Disease activity was defined according to the International Ankylosing Spondylitis Assessment Study criteria. The 10-year CV risk (%) profile was evaluated in agreement to the Progetto Cuore criteria. No major CV event was detected in the study population. No significant differences were found when AS pts and controls were compared according to the mean a-IMT (0.52±0.26 vs 0.51±0.13 mm), max-IMT (0.92±0.20 vs 0.85±0.39 mm), prevalence of abnormal max-IMT >1 mm (27.2 vs 5.3%), and 10-year CV risk (9.9±9.6 vs 3.6±1.8%). Systolic blood pressure (p=0.04), triglyceride to HDL cholesterol ratio (p=0.002), and LDL cholesterol (p=0.03) were found significantly higher in AS pts than in controls; on the contrary, HDL cholesterol was pointed out as significantly lower (p<0.001). MetS was found in 11/24 (45.8%) AS pts and in 2/19 (10.5%) controls (p=0.019). No significant relationship emerged in MetS prevalence among AS pts regarding the mean value of age, disease duration, Bath Ankylosing Spondylitis Functional Index, Bath Ankylosing Spondylitis Disease Activity Index, and the Italian version of Health Assessment Questionnaire. This preliminary report points out a higher prevalence of MetS in AS pts than in controls. Further studies are needed to confirm this finding.
Literature
1.
go back to reference Van Der Linden S, Van Der Hejde D, Braun J (2005) Ankylosing spondylitis. In: Harris ED, Budd RC, Firestein GS, Genovese MC, Sargent JS, Ruddy S, Sledge CB (eds) Kelly’s textbook of rheumatology, 7th edn. Saunders, Philadelphia, PA, pp 1125–1141 Van Der Linden S, Van Der Hejde D, Braun J (2005) Ankylosing spondylitis. In: Harris ED, Budd RC, Firestein GS, Genovese MC, Sargent JS, Ruddy S, Sledge CB (eds) Kelly’s textbook of rheumatology, 7th edn. Saunders, Philadelphia, PA, pp 1125–1141
2.
go back to reference Kaprove RE, Little AH, Graham DC, Rosen PS (1980) Ankylosing spondylitis survival in men with and without radiotherapy. Arthritis Rheum 23:57–61PubMedCrossRef Kaprove RE, Little AH, Graham DC, Rosen PS (1980) Ankylosing spondylitis survival in men with and without radiotherapy. Arthritis Rheum 23:57–61PubMedCrossRef
3.
go back to reference Smith PG, Doll R (1982) Mortality among patients with ankylosing spondylitis after single treatment course with X-rays. BMJ 13:449–460CrossRef Smith PG, Doll R (1982) Mortality among patients with ankylosing spondylitis after single treatment course with X-rays. BMJ 13:449–460CrossRef
4.
go back to reference Lehtinen K (1993) Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 52:174–176PubMed Lehtinen K (1993) Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 52:174–176PubMed
5.
go back to reference O’Neill TW, Bresnihan B (1992) The heart in ankylosing spondylitis. Ann Rheum Dis 51:705–706PubMed O’Neill TW, Bresnihan B (1992) The heart in ankylosing spondylitis. Ann Rheum Dis 51:705–706PubMed
6.
go back to reference O’Neill TW, King G, Graham IM, Molony J, Bresnihan B (1992) Echocardiographic abnormalities in ankylosing spondylitis. Ann Rheum Dis 51:652–654PubMedCrossRef O’Neill TW, King G, Graham IM, Molony J, Bresnihan B (1992) Echocardiographic abnormalities in ankylosing spondylitis. Ann Rheum Dis 51:652–654PubMedCrossRef
7.
go back to reference Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT (2004) Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34:585–592PubMedCrossRef Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT (2004) Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34:585–592PubMedCrossRef
8.
go back to reference Sari I, Okan T, Akan S, Cece H, Altay C, Secil M et al (2006) Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology 45:283–286PubMedCrossRef Sari I, Okan T, Akan S, Cece H, Altay C, Secil M et al (2006) Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology 45:283–286PubMedCrossRef
9.
go back to reference Kahn R, Buse J, Ferrannini E, Stern M (2005) The metabolic syndrome: time for a critical appraisal. Diabetes Care 28:2289–2304PubMedCrossRef Kahn R, Buse J, Ferrannini E, Stern M (2005) The metabolic syndrome: time for a critical appraisal. Diabetes Care 28:2289–2304PubMedCrossRef
10.
go back to reference Rutter MK, Meigs JB, Sullivan LM, D’Agostino RB Sr, Wilson PW (2004) C-reactive protein, the metabolic syndrome and prediction of cardiovascular events in the Framingham Offsprings Study. Circulation 110:380–385PubMedCrossRef Rutter MK, Meigs JB, Sullivan LM, D’Agostino RB Sr, Wilson PW (2004) C-reactive protein, the metabolic syndrome and prediction of cardiovascular events in the Framingham Offsprings Study. Circulation 110:380–385PubMedCrossRef
11.
go back to reference Ridker MK, Wilson PW, Grundy SM (2004) Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 109:2818–2825PubMedCrossRef Ridker MK, Wilson PW, Grundy SM (2004) Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 109:2818–2825PubMedCrossRef
12.
go back to reference Van Der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 27:361–368PubMedCrossRef Van Der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 27:361–368PubMedCrossRef
13.
go back to reference Dougados M, Van Der Linden S, Juhlin R, Huitfeldt T, Amor B, Calin A et al (1991) The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy. Arthritis Rheum 34:1218–1227PubMedCrossRef Dougados M, Van Der Linden S, Juhlin R, Huitfeldt T, Amor B, Calin A et al (1991) The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy. Arthritis Rheum 34:1218–1227PubMedCrossRef
14.
go back to reference Bond MG, Barnes RW, Wiley WA, Wilmoth SK, Chambless LE, Howard G et al (1991) High-resolution B-mode ultrasound reading methods in the Atherosclerosis Risk in Communities (ARIC) cohort. The ARIC Study Group. J Neuroimaging 1:68–73 Bond MG, Barnes RW, Wiley WA, Wilmoth SK, Chambless LE, Howard G et al (1991) High-resolution B-mode ultrasound reading methods in the Atherosclerosis Risk in Communities (ARIC) cohort. The ARIC Study Group. J Neuroimaging 1:68–73
15.
go back to reference Howard G, Sharrett R, Heiss G, Evans GW, Chambless LE, Riley WA et al (1993) Carotid artery intima-media thickness distribution in general populations as evaluated by B-mode ultrasound. Stroke 24:297–304 Howard G, Sharrett R, Heiss G, Evans GW, Chambless LE, Riley WA et al (1993) Carotid artery intima-media thickness distribution in general populations as evaluated by B-mode ultrasound. Stroke 24:297–304
16.
go back to reference Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18:499–502PubMed Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18:499–502PubMed
17.
go back to reference Giampaoli S, Palmieri L, Chiodini P, Ferrario M, Panico S, Pilotto L et al (2004) La carta del rischio cardiovascolare globale. Ital Heart J 5(Suppl 3):177–185 Giampaoli S, Palmieri L, Chiodini P, Ferrario M, Panico S, Pilotto L et al (2004) La carta del rischio cardiovascolare globale. Ital Heart J 5(Suppl 3):177–185
18.
go back to reference Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al (2005) Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Circulation 112:e285–e290CrossRef Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al (2005) Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Circulation 112:e285–e290CrossRef
19.
go back to reference Braun J, Pharm T, Sieper J, Davis J, Van Der Linden SJ, Dougados M et al (2003) International ASAS consensus statement for the use of anti-tumor necrosis agents in patients with ankylosing spondylitis. Ann Rheum Dis 62:817–824PubMedCrossRef Braun J, Pharm T, Sieper J, Davis J, Van Der Linden SJ, Dougados M et al (2003) International ASAS consensus statement for the use of anti-tumor necrosis agents in patients with ankylosing spondylitis. Ann Rheum Dis 62:817–824PubMedCrossRef
20.
go back to reference Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Malorie P et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285PubMed Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Malorie P et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285PubMed
21.
go back to reference Ranza R, Marchesoni A, Calori G, Bianchi G, Braga M, Canazza S et al (1993) The Italian version of the functional disability index of the health assessment questionnaire. A reliable instrument for multicenter studies on rheumatoid arthritis. Clin Exp Rheumatol 11:123–128PubMed Ranza R, Marchesoni A, Calori G, Bianchi G, Braga M, Canazza S et al (1993) The Italian version of the functional disability index of the health assessment questionnaire. A reliable instrument for multicenter studies on rheumatoid arthritis. Clin Exp Rheumatol 11:123–128PubMed
22.
go back to reference Dessein PH, Stanwix AE, Joffe BI (2002) Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res 4:R5PubMedCrossRef Dessein PH, Stanwix AE, Joffe BI (2002) Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res 4:R5PubMedCrossRef
23.
go back to reference Magadmi ME, Ahmad Y, Turkie W, Yates AP, Sheikh N, Bernstein RM et al (2006) Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J Rheumatol 33:50–56PubMed Magadmi ME, Ahmad Y, Turkie W, Yates AP, Sheikh N, Bernstein RM et al (2006) Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J Rheumatol 33:50–56PubMed
24.
go back to reference Doran MF, Brophy S, Mackay K, Taylor G, Calin A (2003) Prediction of long term outcome in ankylosing spondylitis. J Rheumatol 30:316–320PubMed Doran MF, Brophy S, Mackay K, Taylor G, Calin A (2003) Prediction of long term outcome in ankylosing spondylitis. J Rheumatol 30:316–320PubMed
25.
go back to reference Divecha H, Sattar N, Rumley A, Cherry L, Loe GD, Sturrock R (2005) Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation. Clin Sci (Lond) 109:171–176CrossRef Divecha H, Sattar N, Rumley A, Cherry L, Loe GD, Sturrock R (2005) Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation. Clin Sci (Lond) 109:171–176CrossRef
26.
go back to reference Joven J, Rubies-Prat J, Ras MR, de la Figuera M, Lience E, Masdeu S (1984) High density lipoproteins cholesterol subfractions and apoprotein A-I in patients with rheumatoid arthritis and ankylosing spondylitis. Arthritis Rheum 27:1199–2000PubMedCrossRef Joven J, Rubies-Prat J, Ras MR, de la Figuera M, Lience E, Masdeu S (1984) High density lipoproteins cholesterol subfractions and apoprotein A-I in patients with rheumatoid arthritis and ankylosing spondylitis. Arthritis Rheum 27:1199–2000PubMedCrossRef
27.
go back to reference Alves MG, Espirito-Santo J, Queiroz MV, Madeira H, Maciera-Coelho E (1988) Cardiac alterations in ankylosing spondylitis. Angiology 39:67–571 Alves MG, Espirito-Santo J, Queiroz MV, Madeira H, Maciera-Coelho E (1988) Cardiac alterations in ankylosing spondylitis. Angiology 39:67–571
28.
go back to reference Magi L, Stramenga C, Morosini P (2005) Prevalence of the metabolic syndrome among Italian adults. Findings from the SIMAP study. Recenti Prog Med 96:280–283PubMed Magi L, Stramenga C, Morosini P (2005) Prevalence of the metabolic syndrome among Italian adults. Findings from the SIMAP study. Recenti Prog Med 96:280–283PubMed
29.
go back to reference Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K (2004) Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in non diabetic European men and women. Arch Intern Med 164:1066–1076PubMedCrossRef Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K (2004) Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in non diabetic European men and women. Arch Intern Med 164:1066–1076PubMedCrossRef
30.
go back to reference Malik S, Wong ND, Franklin SS, Kamath TV, L’italein GJ, Pio JR et al (2004) Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110:1245–1250PubMedCrossRef Malik S, Wong ND, Franklin SS, Kamath TV, L’italein GJ, Pio JR et al (2004) Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110:1245–1250PubMedCrossRef
31.
go back to reference Lorenzo C, Okoloise M, Williams K, Stern MP, Hafner SM (2003) The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care 26:3153–3156PubMedCrossRef Lorenzo C, Okoloise M, Williams K, Stern MP, Hafner SM (2003) The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care 26:3153–3156PubMedCrossRef
32.
go back to reference Dessein PH, Joffe BI, Stanwix A, Botha AS, Moomal Z (2002) The acute phase response does not fully predict the presence of insulin resistance and dyslipidemia in inflammatory arthritis. J Rheumatol 29:462–466PubMed Dessein PH, Joffe BI, Stanwix A, Botha AS, Moomal Z (2002) The acute phase response does not fully predict the presence of insulin resistance and dyslipidemia in inflammatory arthritis. J Rheumatol 29:462–466PubMed
33.
go back to reference Dessein PH, Joffe BI, Stanwix AE (2005) Should we evaluate insulin sensitivity in the rheumatoid arthritis? Semin Arthritis Rheum 35:5–7PubMedCrossRef Dessein PH, Joffe BI, Stanwix AE (2005) Should we evaluate insulin sensitivity in the rheumatoid arthritis? Semin Arthritis Rheum 35:5–7PubMedCrossRef
34.
go back to reference Stamler J, Stamler R, Neaton JD (1993) Blood pressure, systolic and diastolic and cardiovascular risks. U.S. population data. Arch Intern Med 153:598–615PubMedCrossRef Stamler J, Stamler R, Neaton JD (1993) Blood pressure, systolic and diastolic and cardiovascular risks. U.S. population data. Arch Intern Med 153:598–615PubMedCrossRef
35.
go back to reference Kannel WB, Larson M (1993) Long-term epidemiologic prediction of coronary disease. The Framingham experience. Cardiology 82:137–152PubMedCrossRef Kannel WB, Larson M (1993) Long-term epidemiologic prediction of coronary disease. The Framingham experience. Cardiology 82:137–152PubMedCrossRef
Metadata
Title
High prevalence of metabolic syndrome in patients with ankylosing spondylitis
Authors
Domenico Malesci
Alferio Niglio
Gianna Angela Mennillo
Rosario Buono
Gabriele Valentini
Giovanni La Montagna
Publication date
01-05-2007
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 5/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-006-0380-5

Other articles of this Issue 5/2007

Clinical Rheumatology 5/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.